GRRMF: AI 评分 43/100 — AI 分析 (4月 2026)

Gerresheimer AG is a global manufacturer of packaging products and drug delivery devices, operating through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. The company serves the pharmaceutical, biotech, diagnostics, and medical technology industries.

Key Facts: AI Score: 43/100 Sector: Healthcare

公司概况

概要：

Gerresheimer AG manufactures specialized packaging solutions and drug delivery systems for the healthcare industry, focusing on plastics, glass, and advanced technologies. With a global presence and a history dating back to 1864, the company serves pharmaceutical, biotech, and cosmetic sectors with a diverse product portfolio.

GRRMF是做什么的？

Founded in 1864 and headquartered in Düsseldorf, Germany, Gerresheimer AG has evolved into a leading global manufacturer of packaging products and drug delivery devices. The company operates through three primary divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers a range of drug delivery systems, including inhalers, insulin pen systems, and prefillable syringes, along with diagnostic systems for the pharma, biotech, diagnostics, and medical technology industries. This division also provides containers and closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and accessories for solid, liquid, and ophthalmic applications, as well as bottles and containers for nutritional supplements. The Primary Packaging Glass division focuses on glass primary packaging for the pharma and cosmetics industries, producing infusion, dropper, and syrup bottles, injection vials, ampoules, and cartridges. Additionally, it offers miniature bottles and glass containers for liquid food, spices, and spirits, along with packaging solutions for fragrances, deodorants, skin care, and wellness products, as well as beauty and pharmaceutical products. The Advanced Technologies division is dedicated to developing smart drug delivery systems, such as micro pumps, which are used to self-administer medication for conditions like Parkinson's disease or heart failure. Gerresheimer serves a diverse customer base across the pharmaceutical, biotech, diagnostics, medical technology, and cosmetics industries, with a global footprint that allows it to cater to both established and emerging markets.

GRRMF的投资论点是什么？

Gerresheimer AG presents an investment opportunity within the healthcare sector, driven by its diverse product portfolio and global presence. The company's focus on drug delivery systems and specialized packaging caters to the growing demand for advanced healthcare solutions. With a market capitalization of $0.75 billion and a P/E ratio of 26.14, Gerresheimer exhibits a moderate valuation. Key growth catalysts include the expansion of its Advanced Technologies division and increasing demand for injectable drugs. However, the may be worth researching company's relatively low profit margin of 1.0% and potential risks associated with regulatory changes and competition. The dividend yield is 0.23%.

GRRMF在哪个行业运营？

Gerresheimer AG operates in the medical instruments and supplies industry, which is characterized by continuous innovation and stringent regulatory requirements. The market is driven by increasing healthcare expenditure, an aging population, and the rising prevalence of chronic diseases. The competitive landscape includes companies like BOEUF, EBOSY, EKTAF, EKTAY, and GENSF, each vying for market share through product differentiation and strategic partnerships. Trends such as personalized medicine and the growing demand for self-administered drug delivery systems are shaping the industry's future.

Medical - Instruments & Supplies

Healthcare

GRRMF有哪些增长机遇？

Expansion of Advanced Technologies Division: Gerresheimer's Advanced Technologies division, which develops smart drug delivery systems like micro pumps, represents a significant growth opportunity. The market for advanced drug delivery systems is projected to reach $24.7 billion by 2027, driven by the increasing demand for personalized medicine and self-administration options. By focusing on innovative solutions for chronic diseases like Parkinson's and heart failure, Gerresheimer can capture a larger share of this expanding market. Timeline: Ongoing.
Increasing Demand for Injectable Drugs: The rising prevalence of chronic diseases and the growing biologics market are driving increased demand for injectable drugs, creating a significant opportunity for Gerresheimer's Plastics & Devices division. The global injectable drug market is expected to reach $790.7 billion by 2030. Gerresheimer's expertise in manufacturing prefillable syringes and other injectable drug delivery systems positions it well to capitalize on this trend. Timeline: Ongoing.
Growth in Emerging Markets: Emerging markets, with their rapidly growing populations and increasing healthcare expenditure, present a substantial growth opportunity for Gerresheimer. These markets are experiencing a rising demand for pharmaceutical packaging and drug delivery systems. By expanding its presence in regions like Asia-Pacific and Latin America, Gerresheimer can tap into new revenue streams and diversify its geographic footprint. Timeline: Ongoing.
Strategic Partnerships and Acquisitions: Gerresheimer can pursue strategic partnerships and acquisitions to expand its product portfolio, enhance its technological capabilities, and strengthen its market position. Collaborating with pharmaceutical companies and biotech firms can facilitate the development of innovative drug delivery solutions and secure long-term supply contracts. Acquisitions of complementary businesses can provide access to new markets and technologies. Timeline: Ongoing.
Focus on Sustainable Packaging Solutions: With increasing environmental awareness, there is a growing demand for sustainable packaging solutions in the healthcare industry. Gerresheimer can capitalize on this trend by developing and offering eco-friendly packaging options, such as recyclable plastics and bio-based materials. By positioning itself as a leader in sustainable packaging, Gerresheimer can attract environmentally conscious customers and gain a competitive advantage. Timeline: Ongoing.

Market capitalization of $0.75 billion indicates a mid-sized player in the medical instruments and supplies market.
P/E ratio of 26.14 suggests a moderate valuation compared to its earnings.
Profit margin of 1.0% reflects a need for improved operational efficiency.
Gross margin of 26.9% indicates the profitability of its products before operating expenses.
Dividend yield of 0.23% provides a modest income stream for investors.

GRRMF提供哪些产品和服务？

Manufactures plastic containers and closures for liquid and solid pharmaceuticals.
Produces glass vials, ampoules, and cartridges for injectable drugs.
Develops and manufactures drug delivery systems, including inhalers and pen systems.
Offers packaging solutions for the cosmetics and personal care industries.
Creates advanced micro pumps for self-administration of medication.
Provides diagnostic systems for the pharma and biotech sectors.

GRRMF如何赚钱？

Manufacturing and selling primary packaging glass for pharmaceutical and cosmetic products.
Producing plastic containers and drug delivery systems for the healthcare industry.
Developing and commercializing advanced drug delivery technologies.
Generating revenue through long-term supply contracts with pharmaceutical companies.

Pharmaceutical companies requiring primary packaging for drugs.
Biotech firms needing drug delivery systems for injectable medications.
Cosmetics companies seeking packaging solutions for beauty products.
Healthcare providers using diagnostic systems and drug delivery devices.

Specialized Expertise: Gerresheimer's deep expertise in manufacturing specialized packaging and drug delivery systems creates a barrier to entry for new competitors.
Long-Term Relationships: The company's long-standing relationships with pharmaceutical companies and biotech firms provide a stable revenue stream and a competitive advantage.
Regulatory Compliance: Gerresheimer's adherence to stringent regulatory requirements in the healthcare industry ensures product quality and safety, building trust with customers.
Global Footprint: The company's global manufacturing and distribution network allows it to serve customers in both established and emerging markets.

什么因素可能推动GRRMF股价上涨？

Ongoing: Expansion of the Advanced Technologies division with new product launches in micro pumps and smart drug delivery systems.
Ongoing: Increasing demand for injectable drugs driving growth in the Plastics & Devices division.
Ongoing: Strategic partnerships and acquisitions to expand product portfolio and market reach.
Upcoming: Potential regulatory approvals for new drug delivery devices in key markets.
Ongoing: Focus on sustainable packaging solutions attracting environmentally conscious customers.

GRRMF的主要风险是什么？

Potential: Intense competition from established players and new entrants in the healthcare packaging market.
Potential: Stringent regulatory requirements and potential product recalls affecting product sales and reputation.
Potential: Economic downturns affecting healthcare spending and demand for pharmaceutical products.
Ongoing: Exposure to currency fluctuations due to its global operations.
Ongoing: Relatively low profit margin compared to industry peers, requiring improved operational efficiency.

GRRMF的核心优势是什么？

Global presence and established reputation in the healthcare industry.
Diverse product portfolio spanning packaging, drug delivery systems, and advanced technologies.
Long-standing relationships with major pharmaceutical companies.
Expertise in regulatory compliance and quality control.

GRRMF的劣势是什么？

Relatively low profit margin compared to industry peers.
Dependence on the pharmaceutical industry, making it susceptible to regulatory changes.
Limited brand recognition among consumers.
Exposure to currency fluctuations due to its global operations.

GRRMF有哪些机遇？

Expanding into emerging markets with growing healthcare expenditure.
Developing innovative drug delivery systems for chronic diseases.
Acquiring complementary businesses to expand its product portfolio.
Capitalizing on the increasing demand for sustainable packaging solutions.

GRRMF面临哪些威胁？

Intense competition from established players and new entrants.
Stringent regulatory requirements and potential product recalls.
Economic downturns affecting healthcare spending.
Disruptive technologies that could render existing products obsolete.

GRRMF的竞争对手是谁？

B. Braun Melsungen AG — Offers a broader range of healthcare products, including medical devices and hospital supplies. — (BOEUF)
EBOS Group Ltd — Focuses on healthcare and animal care products, with a significant presence in Australia and New Zealand. — (EBOSY)
Eckert & Ziegler Strahlen- und Medizintechnik AG — Specializes in isotope technology for medical and industrial applications. — (EKTAF)
Eckert & Ziegler Strahlen- und Medizintechnik AG — Specializes in isotope technology for medical and industrial applications. — (EKTAY)
Genus PLC — Focuses on animal genetics and reproduction, serving the agriculture industry. — (GENSF)

Key Metrics

MoonshotScore: 43/100

Company Profile

CEO: Uwe Ferdinand Röehrhoff
Headquarters: Düsseldorf, DE
Employees: 13,632
Founded: 2009

AI Insight

AI analysis pending for GRRMF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Gerresheimer AG do?

Gerresheimer AG is a global manufacturer of packaging products and drug delivery devices, primarily serving the pharmaceutical, biotech, diagnostics, and medical technology industries. The company operates through three divisions: Plastics & Devices, which offers drug delivery systems and containers; Primary Packaging Glass, which provides glass packaging for pharma and cosmetics; and Advanced Technologies, which develops smart drug delivery systems. Gerresheimer's products are essential for the safe and effective delivery of medications and healthcare products worldwide.

What do analysts say about GRRMF stock?

Analyst sentiment on GRRMF stock is currently pending AI analysis. Key valuation metrics include a market capitalization of $0.75 billion and a P/E ratio of 26.14. Growth considerations revolve around the company's ability to expand its Advanced Technologies division and capitalize on the increasing demand for injectable drugs. Investors should monitor the company's financial performance, regulatory developments, and competitive landscape to assess its future growth potential. No buy or sell recommendations are made here.

What are the main risks for GRRMF?

The main risks for Gerresheimer AG include intense competition in the healthcare packaging market, stringent regulatory requirements and potential product recalls, economic downturns affecting healthcare spending, exposure to currency fluctuations, and a relatively low profit margin. The company's dependence on the pharmaceutical industry also makes it susceptible to regulatory changes and pricing pressures. Investors should carefully consider these risks before investing in GRRMF.